OBT-676

OBT-676 is an orally bioavailable small molecule agonist developed by Oban BioPharma for the treatment of metabolic diseases, including obesity and type 2 diabetes. It features a unique multi-receptor pharmacology, acting as a full agonist at the amylin (AMY-1 and AMY-3) and calcitonin receptors (Dual Amylin and Calcitonin Receptor Agonism, or DACRA), while simultaneously providing partial agonism at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (the "Triple-G" component). This synergistic mechanism is designed to enhance appetite suppression, promote weight loss, and improve insulin sensitivity. In preclinical studies using diet-induced obesity (DIO) rat models, oral administration of OBT-676 significantly reduced acute food intake.